dihydropyridines and Kidney-Neoplasms

dihydropyridines has been researched along with Kidney-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for dihydropyridines and Kidney-Neoplasms

ArticleYear
Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas.
    Cancer, 1993, Jun-01, Volume: 71, Issue:11

    Renal cell carcinomas (RCC) respond poorly to anthracyclines, Vinca alkaloids, and other agents. P-glycoprotein is overproduced in multidrug-resistant cells and thought to function as an energy-dependent drug efflux pump. The authors thus examined the expression level of P-glycoprotein in RCC and transitional cell carcinomas (TCC).. P-glycoprotein was detected using immunoblotting with a monoclonal antibody against it, C219.. Thirty-three of 38 patients with RCC and 3 of 17 patients with TCC had P-glycoprotein positive tumors. The expression level of P-glycoprotein in most of RCC was lower than that in the normal kidney tissues and that of P-glycoprotein in the TCC was very low. The size of P-glycoprotein in 14 RCC and 3 TCC was 5-10 kilodaltons smaller than in the normal renal tissues. The variation of P-glycoprotein size in the RCC was attributed to differential N-linked glycosylation. P-glycoprotein in a RCC was photolabeled by tritiated azidopine, and the labeling was inhibited by some organic agents. P-glycoprotein distributed on the apical or marginal cell surface of the RCC.. These data show that P-glycoprotein was expressed in many RCC, and its expression level, glycosylation, and distribution were altered. These data also suggest that the P-glycoprotein in RCC had similar drug binding site(s) to that in multidrug-resistant cells.

    Topics: Affinity Labels; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carrier Proteins; Dihydropyridines; Drug Resistance; Humans; Immunoblotting; Kidney; Kidney Neoplasms; Membrane Glycoproteins; Neoplasm Proteins

1993
Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas.
    Cancer research, 1990, Jun-15, Volume: 50, Issue:12

    Human renal cell carcinomas display a characteristically high degree of intrinsic chemoresistance to a multitude of chemotherapeutic agents. It was suggested previously, that P-170 glycoprotein contributes to this phenomenon in renal cell carcinoma indicated by elevated MDR-1 gene mRNA levels and by the expression of this specific resistance characteristic. The P-170-related efflux mechanism can be inactivated by certain calcium antagonists. P-170 was traced immunohistochemically using monoclonal antibody C 219. Concomitantly, we studied the enhancement of vinblastine cytotoxicity with 4 major classes of calcium-blocking agents in a microculture tetrazolium assay. Seven different calcium antagonists were selected: verapamil (VPM, racemic form), its R-stereoisomer (R-VPM), diltiazem, flunarizine, nifedipine, and its derivatives nimodipine and nitrendipine. Verapamil or R-verapamil causes a significant decrease of viable tumor cells as compared to vinblastine alone (P less than 0.001). Similar effects were found with diltiazem, nifedipine, and its derivatives reaching approximately 70% of the VPM/R-VPM activity. Flunarizine showed only minor enhancement of cytotoxicity. P-170 expression was demonstrated in 18 of 32 tumors, and a relation to chemoresistance was evident. None of the chemoresponders, but 18 of 25 (72%) of the highly resistant tumors, revealed this resistance factor. It was concluded that certain calcium antagonists in combination with chemotherapy may well offer therapeutic options in renal cell carcinoma as they apparently inactivate the underlying mechanism conferring resistance. The new stereoisomer R-VPM, in particular, may be used in clinical trials since it combines strong enhancement of vinblastine drug responsiveness with a 10-fold lower cardiovascular activity as compared to racemic VPM, thus allowing higher concentrations to be applied.

    Topics: Calcium; Carcinoma, Renal Cell; Chemical Phenomena; Chemistry; Dihydropyridines; Diltiazem; Drug Resistance; Humans; Kidney Neoplasms; Papaverine; Tumor Cells, Cultured; Vinblastine

1990